EMMA - Biopharma Reports Fifth Quarter of Increased Net Revenues

2023-05-15 10:52:34 ET

Those afflicted with sickle cell disease face many challenges and acute complications. This %Biopharma company is the leader in treatment of the disease and just reported its fifth straight increase in quarterly net revenues.

%EmmausLifeSciences (OTC: ) reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Increased sales in the U.S. and Middle East/North Africa region helped the firm report a fifth straight increase in quarterly net revenues and increased net revenues of 109% year-over-year.

Due to these increases the firm was able to substantially reduce losses from operations and realized income from operations excluding share-based compensation. The firm’s product, Endari® (L-glutamine oral powder), is indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar and the United Arab Emirates and is available on a named patient or early access basis in France, the Netherlands. Shares last traded at $0.32.